Viewing Study NCT02811861

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 12:48 PM
Ignite Modification Date: 2026-04-23 @ 11:07 PM
Study NCT ID: NCT02811861
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-11-01
First Post: 2016-06-21
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Sponsor:
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Raw JSON

{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002292', 'term': 'Carcinoma, Renal Cell'}], 'ancestors': [{'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D007680', 'term': 'Kidney Neoplasms'}, {'id': 'D014571', 'term': 'Urologic Neoplasms'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C531958', 'term': 'lenvatinib'}, {'id': 'D000068338', 'term': 'Everolimus'}, {'id': 'C582435', 'term': 'pembrolizumab'}, {'id': 'D000077210', 'term': 'Sunitinib'}], 'ancestors': [{'id': 'D020123', 'term': 'Sirolimus'}, {'id': 'D018942', 'term': 'Macrolides'}, {'id': 'D007783', 'term': 'Lactones'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D011758', 'term': 'Pyrroles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D007211', 'term': 'Indoles'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'esi_oncmedinfo@eisai.com', 'phone': '+1-888-274-2378', 'title': 'Eisai Medical Information', 'organization': 'Eisai, Inc.'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'From first dose of study drug (Baseline) up to 30 days after last dose of study drug or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)', 'description': 'Safety analysis set included all participants who received at least 1 dose of any study drug.', 'eventGroups': [{'id': 'EG000', 'title': 'Lenvatinib 18 mg Plus Everolimus 5 mg', 'description': 'Participants received lenvatinib 18 milligrams (mg) administered orally, once daily in each 21-day cycle, plus everolimus 5 mg administered orally, once daily in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.', 'otherNumAtRisk': 355, 'deathsNumAtRisk': 355, 'otherNumAffected': 353, 'seriousNumAtRisk': 355, 'deathsNumAffected': 119, 'seriousNumAffected': 164}, {'id': 'EG001', 'title': 'Lenvatinib 20 mg Plus Pembrolizumab 200 mg', 'description': 'Participants received lenvatinib 20 mg administered orally, once daily in each 21-day cycle, plus pembrolizumab 200 mg administered intravenously, every 3 weeks in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study.', 'otherNumAtRisk': 352, 'deathsNumAtRisk': 352, 'otherNumAffected': 351, 'seriousNumAtRisk': 352, 'deathsNumAffected': 78, 'seriousNumAffected': 178}, {'id': 'EG002', 'title': 'Sunitinib 50 mg', 'description': 'Participants received sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.', 'otherNumAtRisk': 340, 'deathsNumAtRisk': 340, 'otherNumAffected': 332, 'seriousNumAtRisk': 340, 'deathsNumAffected': 99, 'seriousNumAffected': 113}], 'otherEvents': [{'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 233}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 214}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 166}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Stomatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 169}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 122}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 131}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 139}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 125}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 113}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 107}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 91}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 67}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 73}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 87}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 64}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 72}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 72}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 28}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 34}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 39}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 55}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Abdominal pain upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 45}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 34}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 26}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Dry mouth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 23}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 36}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 11}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Gastrooesophageal reflux disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 16}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 16}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 30}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Toothache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 24}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 19}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 9}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Haemorrhoids', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 19}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 20}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 11}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Abdominal discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 19}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 8}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 149}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 141}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 124}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 63}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 77}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 61}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 72}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 42}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 35}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 44}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 48}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 41}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Weight decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 116}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 105}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 31}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Platelet count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 59}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 21}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 61}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Lipase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 22}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 64}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 44}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 52}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 39}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 37}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 49}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 42}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 35}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Blood creatinine increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 36}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 48}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 34}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Amylase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 16}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 62}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 28}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Blood thyroid stimulating hormone increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 22}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 39}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 21}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Blood cholesterol increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 41}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 24}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 14}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Neutrophil count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 40}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Blood triglycerides increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 21}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 22}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 15}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'White blood cell count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 33}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Blood creatine phosphokinase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 19}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 14}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 17}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Electrocardiogram QT prolonged', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 15}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 22}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 13}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Blood alkaline phosphatase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 20}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 17}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 9}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Palmar-plantar erythrodysaesthesia syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 81}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 101}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 127}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 87}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 95}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 47}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 47}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 58}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 26}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Dry skin', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 31}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 22}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 27}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Rash maculo-papular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 23}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 28}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 7}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Yellow skin', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 32}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Dermatitis acneiform', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 23}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 3}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Decreased appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 143}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 142}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 105}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypertriglyceridaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 80}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 42}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 41}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypercholesterolaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 37}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 31}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 7}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hyperglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 31}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 24}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 18}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypophosphataemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 32}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 22}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 15}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hyponatraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 27}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 20}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypokalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 30}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 22}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 11}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hyperkalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 27}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 18}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 75}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 99}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 52}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 60}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 57}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 52}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Musculoskeletal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 39}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 48}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 21}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 33}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 41}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 33}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 34}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 56}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 12}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Muscle spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 24}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 12}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Musculoskeletal chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 20}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 16}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 11}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 84}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 70}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 53}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Dysphonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 84}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 105}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 14}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 50}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 51}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 32}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Epistaxis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 70}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 25}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 37}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 33}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 23}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 12}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pneumonitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 19}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 12}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 162}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 194}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 141}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 24}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 6}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 34}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 40}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 25}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 32}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 24}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 23}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 19}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 81}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 80}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 54}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Dysgeusia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 59}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 42}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 95}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 34}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 29}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Haematuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 15}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 17}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 19}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypothyroidism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 95}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 164}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 90}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hyperthyroidism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 28}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 12}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 57}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 43}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 66}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 39}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 14}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 53}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 46}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 23}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 40}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 38}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 21}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypomagnesaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 27}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 13}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 24}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 31}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 21}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Proteinuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 121}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 104}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 43}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}], 'seriousEvents': [{'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 4}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Blood loss anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Eosinophilia myalgia syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Febrile neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 5}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Thrombotic thrombocytopenic purpura', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Acute coronary syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Acute myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Angina unstable', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Arrhythmia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Atrial fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Atrial flutter', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Bradycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cardiac arrest', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cardiac failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cardiac failure acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cardiac failure congestive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cardio-respiratory arrest', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cardiogenic shock', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cardiomyopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Congestive cardiomyopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Myocarditis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pericardial effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Postinfarction angina', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Stress cardiomyopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Ventricular arrhythmia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Adrenal insufficiency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypophysitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypopituitarism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypothyroidism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Secondary hypothyroidism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Steroid withdrawal syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cataract', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Eyelid ptosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Retinal vascular occlusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Retinal vein occlusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Vogt-Koyanagi-Harada disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Abdominal hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Abdominal pain upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Anal fissure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Anal fistula', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Ascites', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Colitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Colonic fistula', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 12}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Diverticular perforation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Duodenal ulcer perforation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Dysphagia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Enteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Enterocolitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Eosinophilic gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Food poisoning', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Gastric haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Gastric ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Gastroduodenal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Gastrointestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Haematemesis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Ileus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Immune-mediated enterocolitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Immune-mediated pancreatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Inguinal hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Intestinal obstruction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Intestinal perforation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Intra-abdominal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Large intestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Large intestine perforation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Lower gastrointestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Mallory-Weiss syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Mechanical ileus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Melaena', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Obstructive pancreatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Odynophagia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pancreatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pancreatitis acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Proctitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Retroperitoneal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Small intestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Subileus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Upper gastrointestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 4}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Face oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'General physical health deterioration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Generalised oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Inadequate analgesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Malaise', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Multiple organ dysfunction syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Non-cardiac chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 7}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Autoimmune hepatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Bile duct obstruction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Bile duct stone', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Biliary colic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cholangitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cholecystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cholecystitis acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cholecystitis chronic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cholelithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Drug-induced liver injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hepatic function abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Immune-mediated hepatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Portal vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Abdominal infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Acute sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Anal abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Appendicitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Bacteraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'COVID-19 pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cellulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cholecystitis infective', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Clostridium difficile infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Colonic abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Diverticulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Ear infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Empyema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Encephalitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Encephalitis viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Enteritis infectious', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Enterocolitis infectious', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Gastroenteritis viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Infectious pleural effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Klebsiella sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Localised infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Necrotising fasciitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Oropharyngeal candidiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Osteomyelitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Otitis externa', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Peritonitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Peritonitis bacterial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Peritonsillar abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pneumocystis jirovecii pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 15}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pneumonia influenzal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pneumonia necrotising', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Postoperative wound infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Prostatic abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pyelonephritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Retroperitoneal abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Septic arthritis staphylococcal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Skin infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Staphylococcal bacteraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Subdiaphragmatic abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Urosepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Wound infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Accidental overdose', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Arterial injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Femoral neck fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Femur fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Head injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Incisional hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Infusion related reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Lower limb fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Radiation injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Radiation proctitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Rib fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Spinal cord injury cervical', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Spinal fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Stress fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Subdural haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Tibia fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Toxicity to various agents', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Upper limb fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Wound dehiscence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Amylase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Blood bilirubin increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Blood calcium increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Blood creatinine increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Ejection fraction decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Electrocardiogram T wave inversion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Electrocardiogram change', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Glomerular filtration rate decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Haemoglobin increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hepatic enzyme increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Lipase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Neutrophil count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Platelet count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Transaminases increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Troponin increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Weight decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'White blood cell count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cachexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Decreased appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Dehydration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 4}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Diabetes mellitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Diabetic ketoacidosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Electrolyte imbalance', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypercalcaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypercholesterolaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hyperglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hyperglycaemic hyperosmolar nonketotic syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hyperkalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypocalcaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypoglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hyponatraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypophosphataemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 4}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Bone lesion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Bone pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Flank pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Musculoskeletal chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Musculoskeletal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Myositis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Neck pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Osteonecrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Osteoporotic fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pathological fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Spinal stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cancer pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Chronic myeloid leukaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'External ear neoplasm malignant', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Malignant ascites', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Malignant neoplasm progression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Malignant pleural effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Metastases to bone', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Metastases to central nervous system', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Metastases to chest wall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Metastases to lung', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Metastases to skin', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Metastases to spine', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pericardial effusion malignant', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Prostate cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Tumour associated fever', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Tumour haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Tumour pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Ataxia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Carotid artery stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cerebral ischaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cerebrovascular accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cytotoxic oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Dementia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Depressed level of consciousness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Dysgeusia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Encephalopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Generalised tonic-clonic seizure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Haemorrhage intracranial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypertensive encephalopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Ischaemic stroke', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Loss of consciousness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Myasthenic syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Noninfective encephalitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Paralysis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Paralysis recurrent laryngeal nerve', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Paraparesis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Peripheral sensory neuropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Posterior reversible encephalopathy syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Seizure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Spinal cord compression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Subarachnoid haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Transient ischaemic attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Device deposit issue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Product Issues', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Confusional state', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Delirium', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Mania', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Mental status changes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Acute kidney injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 5}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Haematuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 4}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Haemorrhage urinary tract', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Nephritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Oliguria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Proteinuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Renal failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Renal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Ureterolithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Urinary retention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Urinary tract obstruction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Scrotal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Acute respiratory distress syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Bronchial obstruction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Chronic obstructive pulmonary disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Epistaxis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Haemoptysis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Haemothorax', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypoxia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Interstitial lung disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Lung disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pleural effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 5}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pneumonia aspiration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pneumonitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pneumothorax', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pneumothorax spontaneous', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pulmonary embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 3}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pulmonary haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pulmonary mass', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Erythema multiforme', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hyperhidrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Pyoderma gangrenosum', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Rash maculo-papular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Skin ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Stevens-Johnson syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Toxic epidermal necrolysis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Urticaria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Spinal laminectomy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Aneurysm ruptured', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Aortic dissection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Aortic stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Deep vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Embolism venous', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypertensive crisis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 2}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Peripheral ischaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Phlebitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Thrombophlebitis migrans', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Cholestasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}, {'term': 'Rhabdomyolysis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 355, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 352, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 340, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Progression-free Survival (PFS) by Independent Imaging Review (IIR)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '357', 'groupId': 'OG000'}, {'value': '355', 'groupId': 'OG001'}, {'value': '357', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Lenvatinib 18 mg Plus Everolimus 5 mg', 'description': 'Participants received lenvatinib 18 milligrams (mg) administered orally, once daily in each 21-day cycle, plus everolimus 5 mg administered orally, once daily in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.'}, {'id': 'OG001', 'title': 'Lenvatinib 20 mg Plus Pembrolizumab 200 mg', 'description': 'Participants received lenvatinib 20 mg administered orally, once daily in each 21-day cycle, plus pembrolizumab 200 mg administered intravenously, every 3 weeks in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study.'}, {'id': 'OG002', 'title': 'Sunitinib 50 mg', 'description': 'Participants received sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.'}], 'classes': [{'categories': [{'measurements': [{'value': '14.7', 'groupId': 'OG000', 'lowerLimit': '11.1', 'upperLimit': '16.7'}, {'value': '23.9', 'groupId': 'OG001', 'lowerLimit': '20.8', 'upperLimit': '27.7'}, {'value': '9.2', 'groupId': 'OG002', 'lowerLimit': '6.0', 'upperLimit': '11.0'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Stratified Hazard Ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.65', 'ciLowerLimit': '0.53', 'ciUpperLimit': '0.80', 'statisticalMethod': 'Stratified Log-rank Test', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Hazard ratio is based on a Cox Proportional Hazards Model including treatment group as a factor.'}, {'pValue': '<0.0001', 'groupIds': ['OG001', 'OG002'], 'paramType': 'Stratified Hazard Ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.39', 'ciLowerLimit': '0.32', 'ciUpperLimit': '0.49', 'statisticalMethod': 'Stratified Log-rank Test', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Hazard ratio is based on a Cox Proportional Hazards Model including treatment group as a factor.'}], 'paramType': 'MEDIAN', 'timeFrame': 'From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)', 'description': 'PFS assessed by IIR was defined as the time from the date of randomization to the date of the first documentation of progressive disease (PD) or death (whichever occurred first) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1). PD was defined as at least a 20 percent (%) increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS was analyzed using Kaplan-Meier method.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all randomized participants regardless of the treatment actually received.'}, {'type': 'SECONDARY', 'title': 'Objective Response Rate (ORR)', 'timeFrame': 'Up to approximately 69 months', 'description': 'ORR is defined as the proportion of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by IIR using RECIST 1.1. CR is defined as disappearance of all (targeted and non-target \\[NT\\]) lesions. All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\\<) 10mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. To be considered a BOR, all responses had to be confirmed no less than 4 weeks after the initial assessment of response. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2025-07'}, {'type': 'SECONDARY', 'title': 'Overall Survival (OS)', 'timeFrame': 'Up to approximately 69 months', 'description': 'OS is defined as the time from the date of randomization to the date of death from any cause. Participants who were lost to follow-up and those who were alive at the data cutoff date were censored, either at the last date the participant was last known alive or at the data cutoff date, whichever occurred first. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2025-07'}, {'type': 'SECONDARY', 'title': 'Number of Participants With At Least One Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'timeFrame': 'Up to approximately 69 months', 'description': 'TEAEs were defined as those adverse events (AEs) that occurred (or worsened, if present at Baseline) after the first dose of study drug through 30 days after the last dose of study drug.An AE was defined as any untoward medical occurrence in a participants or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with medicinal product. A SAE was defined as any AE if it resulted in death or life-threatening AE or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions or was a congenital anomaly/birth defect. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2025-07'}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Discontinued Treatment Due to Toxicity', 'timeFrame': 'Up to approximately 69 months', 'description': 'Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2025-07'}, {'type': 'SECONDARY', 'title': 'Time to Treatment Failure Due to Toxicity', 'timeFrame': 'Up to approximately 69 months', 'description': 'Time to treatment failure due to toxicity is defined as time from the date of randomization to the date that a participant discontinued study treatment due to TEAEs. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2025-07'}, {'type': 'SECONDARY', 'title': 'Health-Related Quality of Life (HRQoL) Assessed by Functional Assessment of Cancer Therapy Kidney Syndrome Index-Disease-Related Symptoms (FKSI-DRS) Scores', 'timeFrame': 'Up to approximately 69 months', 'description': 'The FKSI-DRS consisted of 9 items that experts and participants had indicated are important targets for the treatment of advanced kidney cancer, and that clinical experts had indicated are primarily disease-related, as opposed to treatment-related. Symptoms assessed on the FKSI-DRS included lack of energy, fatigue, weight loss, pain, bone pain, shortness of breath, cough, fever, or hematuria. Each item was scored on a 5-point Likert-type scale (0 = not at all; 4 = very much) where total score ranged from 0 (worst) to 36 (best), where higher scores correspond to better outcomes. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2025-07'}, {'type': 'SECONDARY', 'title': 'HRQoL Assessed by European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) Score', 'timeFrame': 'Up to approximately 69 months', 'description': 'EORTC QLQ-C30 is a questionnaire including 30 questions that rate the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Scores are transformed to a range of 0 to 100 using a standard EORTC algorithm. For the overall HRQoL and functioning scales, a higher score is correlated with better HRQoL, whereas a higher score represents worse HRQoL for symptom scales. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2025-07'}, {'type': 'SECONDARY', 'title': 'HRQoL Assessed by European Quality of Life (EuroQol) Five-Dimensional, 3-Level (EQ-5D-3L) Score', 'timeFrame': 'Up to approximately 69 months', 'description': 'EQ-5D-3L is a health profile questionnaire consisting of the EQ-5D descriptive system and the EuroQol visual analog scale (EQ-VAS). For the EQ-5D, participants rate 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) at 1 of 3 levels (1=no problems; 2=some problems; 3=extreme problems). The EQ-5D Health Utilities Index (HUI) is derived from the five dimensions of the EQ-5D, using country-specific preference weights (tariffs) to summarize how good or bad each health state is on a scale from 1 (full health) to \\<0 (worse health/dead). The EQ-VAS measures self-rated global health status using a vertically oriented VAS, where 100 represents the "best imaginable health state" and 0 represents the "worst imaginable health state." Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2025-07'}, {'type': 'SECONDARY', 'title': 'PFS on Next-line of Therapy (PFS2)', 'timeFrame': 'Up to approximately 69 months', 'description': 'PFS2 is defined as the time from randomization to disease progression as assessed by investigator on next-line treatment or death from any cause (whichever occurred first). Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2025-07'}, {'type': 'SECONDARY', 'title': 'PFS by Investigator Assessment', 'timeFrame': 'Up to approximately 69 months', 'description': 'PFS by investigator assessment is defined as the time from the date of randomization to the date of first documentation of disease progression based on the investigator assessment per RECIST 1.1 or death (whichever occurred first). Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2025-07'}, {'type': 'SECONDARY', 'title': 'Model-predicted Clearance for Lenvatinib and Everolimus', 'timeFrame': 'Cycles 1 and 2 Day 1; 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 15: predose and 2-12 hours postdose; Cycles 3, 4, 5 and 6 Day 1: predose (Cycle length=21 days)', 'description': 'Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2025-07'}, {'type': 'SECONDARY', 'title': 'Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib and Everolimus', 'timeFrame': 'Cycles 1 and 2 Day 1; 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 15: predose and 2-12 hours postdose; Cycles 3, 4, 5 and 6 Day 1: predose (Cycle length = 21 days', 'description': 'Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2025-07'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Lenvatinib 18 mg Plus Everolimus 5 mg', 'description': 'Participants received lenvatinib 18 milligrams (mg) administered orally, once daily in each 21-day cycle, plus everolimus 5 mg administered orally, once daily in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.'}, {'id': 'FG001', 'title': 'Lenvatinib 20 mg Plus Pembrolizumab 200 mg', 'description': 'Participants received lenvatinib 20 mg administered orally, once daily in each 21-day cycle, plus pembrolizumab 200 mg administered intravenously, every 3 weeks in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study.'}, {'id': 'FG002', 'title': 'Sunitinib 50 mg', 'description': 'Participants received sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '357'}, {'groupId': 'FG001', 'numSubjects': '355'}, {'groupId': 'FG002', 'numSubjects': '357'}]}, {'type': 'Treated', 'achievements': [{'groupId': 'FG000', 'numSubjects': '355'}, {'groupId': 'FG001', 'numSubjects': '352'}, {'groupId': 'FG002', 'numSubjects': '340'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '357'}, {'groupId': 'FG001', 'numSubjects': '355'}, {'groupId': 'FG002', 'numSubjects': '357'}]}], 'dropWithdraws': [{'type': 'Radiological Disease Progression', 'reasons': [{'groupId': 'FG000', 'numSubjects': '123'}, {'groupId': 'FG001', 'numSubjects': '97'}, {'groupId': 'FG002', 'numSubjects': '174'}]}, {'type': 'Clinical Disease Progression', 'reasons': [{'groupId': 'FG000', 'numSubjects': '20'}, {'groupId': 'FG001', 'numSubjects': '19'}, {'groupId': 'FG002', 'numSubjects': '22'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '63'}, {'groupId': 'FG001', 'numSubjects': '60'}, {'groupId': 'FG002', 'numSubjects': '41'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}]}, {'type': 'Subject Choice', 'reasons': [{'groupId': 'FG000', 'numSubjects': '29'}, {'groupId': 'FG001', 'numSubjects': '17'}, {'groupId': 'FG002', 'numSubjects': '23'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '9'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '13'}, {'groupId': 'FG002', 'numSubjects': '3'}]}, {'type': 'Treatment Ongoing at Cutoff Date', 'reasons': [{'groupId': 'FG000', 'numSubjects': '112'}, {'groupId': 'FG001', 'numSubjects': '142'}, {'groupId': 'FG002', 'numSubjects': '67'}]}, {'type': 'Randomized but not treated', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '17'}]}]}], 'recruitmentDetails': 'Participants took part in the study at 181 investigative sites in Austria, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom of Great Britain and Northern Ireland, the United States of America, Australia, Czechia, Israel, Japan, Korea, Russian Federation, from 13 October 2016 to 28 August 2020 (date of data cutoff for the primary analysis of PFS and second interim analysis of Overall Survival).', 'preAssignmentDetails': 'A total of 1417 participants were screened, of which, 1069 were randomized. Of the 1069 randomized, 1047 participants were treated in the study.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '357', 'groupId': 'BG000'}, {'value': '355', 'groupId': 'BG001'}, {'value': '357', 'groupId': 'BG002'}, {'value': '1069', 'groupId': 'BG003'}]}], 'groups': [{'id': 'BG000', 'title': 'Lenvatinib 18 mg Plus Everolimus 5 mg', 'description': 'Participants received lenvatinib 18 milligrams (mg) administered orally, once daily in each 21-day cycle, plus everolimus 5 mg administered orally, once daily in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.'}, {'id': 'BG001', 'title': 'Lenvatinib 20 mg Plus Pembrolizumab 200 mg', 'description': 'Participants received lenvatinib 20 mg administered orally, once daily in each 21-day cycle, plus pembrolizumab 200 mg administered intravenously, every 3 weeks in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study.'}, {'id': 'BG002', 'title': 'Sunitinib 50 mg', 'description': 'Participants received sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.'}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '61.9', 'spread': '10.86', 'groupId': 'BG000'}, {'value': '62.3', 'spread': '10.23', 'groupId': 'BG001'}, {'value': '60.8', 'spread': '9.96', 'groupId': 'BG002'}, {'value': '61.7', 'spread': '10.36', 'groupId': 'BG003'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '91', 'groupId': 'BG000'}, {'value': '100', 'groupId': 'BG001'}, {'value': '82', 'groupId': 'BG002'}, {'value': '273', 'groupId': 'BG003'}]}, {'title': 'Male', 'measurements': [{'value': '266', 'groupId': 'BG000'}, {'value': '255', 'groupId': 'BG001'}, {'value': '275', 'groupId': 'BG002'}, {'value': '796', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '23', 'groupId': 'BG000'}, {'value': '12', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}, {'value': '55', 'groupId': 'BG003'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '328', 'groupId': 'BG000'}, {'value': '339', 'groupId': 'BG001'}, {'value': '334', 'groupId': 'BG002'}, {'value': '1001', 'groupId': 'BG003'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '13', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'categories': [{'title': 'White', 'measurements': [{'value': '254', 'groupId': 'BG000'}, {'value': '263', 'groupId': 'BG001'}, {'value': '270', 'groupId': 'BG002'}, {'value': '787', 'groupId': 'BG003'}]}, {'title': 'Black or African American', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}]}, {'title': 'Asian', 'measurements': [{'value': '77', 'groupId': 'BG000'}, {'value': '81', 'groupId': 'BG001'}, {'value': '67', 'groupId': 'BG002'}, {'value': '225', 'groupId': 'BG003'}]}, {'title': 'American Indian or Alaskan Native', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}]}, {'title': 'Other', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}, {'value': '18', 'groupId': 'BG003'}]}, {'title': 'Missing', 'measurements': [{'value': '16', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}, {'value': '31', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'The full analysis set (FAS) included all randomized participants regardless of the treatment actually received.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2020-08-06', 'size': 1842067, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2021-08-16T07:23', 'hasProtocol': True}, {'date': '2020-08-14', 'size': 773841, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2021-08-16T07:24', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 1069}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2016-10-13', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-07', 'completionDateStruct': {'date': '2026-03-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-10-22', 'studyFirstSubmitDate': '2016-06-21', 'resultsFirstSubmitDate': '2021-08-27', 'studyFirstSubmitQcDate': '2016-06-21', 'lastUpdatePostDateStruct': {'date': '2024-11-01', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2021-08-27', 'studyFirstPostDateStruct': {'date': '2016-06-23', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2021-09-24', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-08-28', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Progression-free Survival (PFS) by Independent Imaging Review (IIR)', 'timeFrame': 'From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)', 'description': 'PFS assessed by IIR was defined as the time from the date of randomization to the date of the first documentation of progressive disease (PD) or death (whichever occurred first) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1). PD was defined as at least a 20 percent (%) increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS was analyzed using Kaplan-Meier method.'}], 'secondaryOutcomes': [{'measure': 'Objective Response Rate (ORR)', 'timeFrame': 'Up to approximately 69 months', 'description': 'ORR is defined as the proportion of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by IIR using RECIST 1.1. CR is defined as disappearance of all (targeted and non-target \\[NT\\]) lesions. All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\\<) 10mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. To be considered a BOR, all responses had to be confirmed no less than 4 weeks after the initial assessment of response. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'Up to approximately 69 months', 'description': 'OS is defined as the time from the date of randomization to the date of death from any cause. Participants who were lost to follow-up and those who were alive at the data cutoff date were censored, either at the last date the participant was last known alive or at the data cutoff date, whichever occurred first. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).'}, {'measure': 'Number of Participants With At Least One Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'timeFrame': 'Up to approximately 69 months', 'description': 'TEAEs were defined as those adverse events (AEs) that occurred (or worsened, if present at Baseline) after the first dose of study drug through 30 days after the last dose of study drug.An AE was defined as any untoward medical occurrence in a participants or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with medicinal product. A SAE was defined as any AE if it resulted in death or life-threatening AE or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions or was a congenital anomaly/birth defect. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).'}, {'measure': 'Number of Participants Who Discontinued Treatment Due to Toxicity', 'timeFrame': 'Up to approximately 69 months', 'description': 'Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).'}, {'measure': 'Time to Treatment Failure Due to Toxicity', 'timeFrame': 'Up to approximately 69 months', 'description': 'Time to treatment failure due to toxicity is defined as time from the date of randomization to the date that a participant discontinued study treatment due to TEAEs. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).'}, {'measure': 'Health-Related Quality of Life (HRQoL) Assessed by Functional Assessment of Cancer Therapy Kidney Syndrome Index-Disease-Related Symptoms (FKSI-DRS) Scores', 'timeFrame': 'Up to approximately 69 months', 'description': 'The FKSI-DRS consisted of 9 items that experts and participants had indicated are important targets for the treatment of advanced kidney cancer, and that clinical experts had indicated are primarily disease-related, as opposed to treatment-related. Symptoms assessed on the FKSI-DRS included lack of energy, fatigue, weight loss, pain, bone pain, shortness of breath, cough, fever, or hematuria. Each item was scored on a 5-point Likert-type scale (0 = not at all; 4 = very much) where total score ranged from 0 (worst) to 36 (best), where higher scores correspond to better outcomes. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).'}, {'measure': 'HRQoL Assessed by European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) Score', 'timeFrame': 'Up to approximately 69 months', 'description': 'EORTC QLQ-C30 is a questionnaire including 30 questions that rate the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Scores are transformed to a range of 0 to 100 using a standard EORTC algorithm. For the overall HRQoL and functioning scales, a higher score is correlated with better HRQoL, whereas a higher score represents worse HRQoL for symptom scales. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).'}, {'measure': 'HRQoL Assessed by European Quality of Life (EuroQol) Five-Dimensional, 3-Level (EQ-5D-3L) Score', 'timeFrame': 'Up to approximately 69 months', 'description': 'EQ-5D-3L is a health profile questionnaire consisting of the EQ-5D descriptive system and the EuroQol visual analog scale (EQ-VAS). For the EQ-5D, participants rate 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) at 1 of 3 levels (1=no problems; 2=some problems; 3=extreme problems). The EQ-5D Health Utilities Index (HUI) is derived from the five dimensions of the EQ-5D, using country-specific preference weights (tariffs) to summarize how good or bad each health state is on a scale from 1 (full health) to \\<0 (worse health/dead). The EQ-VAS measures self-rated global health status using a vertically oriented VAS, where 100 represents the "best imaginable health state" and 0 represents the "worst imaginable health state." Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).'}, {'measure': 'PFS on Next-line of Therapy (PFS2)', 'timeFrame': 'Up to approximately 69 months', 'description': 'PFS2 is defined as the time from randomization to disease progression as assessed by investigator on next-line treatment or death from any cause (whichever occurred first). Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).'}, {'measure': 'PFS by Investigator Assessment', 'timeFrame': 'Up to approximately 69 months', 'description': 'PFS by investigator assessment is defined as the time from the date of randomization to the date of first documentation of disease progression based on the investigator assessment per RECIST 1.1 or death (whichever occurred first). Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).'}, {'measure': 'Model-predicted Clearance for Lenvatinib and Everolimus', 'timeFrame': 'Cycles 1 and 2 Day 1; 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 15: predose and 2-12 hours postdose; Cycles 3, 4, 5 and 6 Day 1: predose (Cycle length=21 days)', 'description': 'Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).'}, {'measure': 'Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib and Everolimus', 'timeFrame': 'Cycles 1 and 2 Day 1; 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 15: predose and 2-12 hours postdose; Cycles 3, 4, 5 and 6 Day 1: predose (Cycle length = 21 days', 'description': 'Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2024).'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Renal Cell Carcinoma (RCC)', 'Lenvatinib', 'First-line RCC', 'Treatment-naive RCC', 'Everolimus', 'Pembrolizumab', 'Sunitinib', 'Phase 3 RCC', 'Phase 3 first-line RCC', 'Phase 3 treatment-naive RCC'], 'conditions': ['Renal Cell Carcinoma']}, 'referencesModule': {'references': [{'pmid': '39885377', 'type': 'DERIVED', 'citation': 'Fawsitt CG, Pan J, Orishaba P, Jackson CH, Thom H. Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma. BMC Med Res Methodol. 2025 Jan 30;25(1):26. doi: 10.1186/s12874-025-02480-x.'}, {'pmid': '39642774', 'type': 'DERIVED', 'citation': 'Zheng H, Zhou J, Tong Y, Zhang J. Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2025 Feb;23(1):102264. doi: 10.1016/j.clgc.2024.102264. Epub 2024 Nov 15.'}, {'pmid': '38582713', 'type': 'DERIVED', 'citation': 'Motzer RJ, Choueiri TK, Hutson T, Young Rha S, Puente J, Lalani AA, Winquist E, Eto M, Basappa NS, Tannir NM, Vaishampayan U, Bjarnason GA, Oudard S, Grunwald V, Burgents J, Xie R, McKenzie J, Powles T. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study. Eur Urol. 2024 Jul;86(1):4-9. doi: 10.1016/j.eururo.2024.03.015. Epub 2024 Apr 6.'}, {'pmid': '38227898', 'type': 'DERIVED', 'citation': 'Motzer RJ, Porta C, Eto M, Powles T, Grunwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Mendez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16.'}, {'pmid': '37664025', 'type': 'DERIVED', 'citation': 'Grunwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Mendez-Vidal MJ, Hong SH, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J, Choueiri TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Front Oncol. 2023 Aug 16;13:1223282. doi: 10.3389/fonc.2023.1223282. eCollection 2023.'}, {'pmid': '37294085', 'type': 'DERIVED', 'citation': 'Rha SY, Choueiri TK, Matveev VB, Alyasova A, Hong SH, Gordoa TA, Gurney H, Bjarnason GA, Buchler T, Pedrazzoli P, Takagi T, Park SH, Lee JL, Perini RF, He CS, McKenzie JA, Eto M. Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial. Int J Cancer. 2023 Sep 15;153(6):1241-1250. doi: 10.1002/ijc.34608. Epub 2023 Jun 9.'}, {'pmid': '37146227', 'type': 'DERIVED', 'citation': 'Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2.'}, {'pmid': '36866412', 'type': 'DERIVED', 'citation': 'Motzer R, George S, Merchan JR, Hutson TE, Song X, Perini RF, Xie R, Bapat U, Puente J. Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab. Oncologist. 2023 Jun 2;28(6):501-509. doi: 10.1093/oncolo/oyac269.'}, {'pmid': '36858721', 'type': 'DERIVED', 'citation': 'Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, Mendez-Vidal MJ, Tjulandin S, Hoon Park S, Melichar B, Hutson T, Alemany C, McGregor B, Powles T, Grunwald V, Alekseev B, Rha SY, Kopyltsov E, Kapoor A, Alonso Gordoa T, Goh JC, Staehler M, Merchan JR, Xie R, Perini RF, Mody K, McKenzie J, Porta CG. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023 Mar;24(3):228-238. doi: 10.1016/S1470-2045(23)00049-9.'}, {'pmid': '35489363', 'type': 'DERIVED', 'citation': 'Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol. 2022 Jun;23(6):768-780. doi: 10.1016/S1470-2045(22)00212-1. Epub 2022 Apr 27.'}, {'pmid': '33616314', 'type': 'DERIVED', 'citation': 'Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grunwald V, Hutson TE, Kopyltsov E, Mendez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.'}, {'pmid': '33058158', 'type': 'DERIVED', 'citation': 'Hofmann F, Hwang EC, Lam TB, Bex A, Yuan Y, Marconi LS, Ljungberg B. Targeted therapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev. 2020 Oct 14;10(10):CD012796. doi: 10.1002/14651858.CD012796.pub2.'}]}, 'descriptionModule': {'briefSummary': 'The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review \\[IIR\\] using Response Evaluation Criteria in Solid Tumors \\[RECIST 1.1\\]) as first-line treatment in participants with advanced renal cell carcinoma (RCC).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Histological or cytological confirmation of RCC with a clear-cell component (original tissue diagnosis of RCC is acceptable).\n2. Documented evidence of advanced RCC.\n3. At least 1 measurable target lesion according to RECIST 1.1 meeting the following criteria:\n\n * Lymph node (LN) lesion that measures at least 1 dimension as greater than or equal to (\\>=) 1.5 cm in the short axis\n * Lymph node (LN) lesion that measures at least 1 dimension as greater than or equal to (\\>=) 1.5 centimeter (cm) in the short axis\n * Non-nodal lesion that measures greater than or equal to (\\>=) 1.0 cm in the longest diameter\n * The lesion is suitable for repeat measurement using computerized tomography/magnetic resonance imaging (CT/MRI). Lesions that have had external beam radiotherapy (EBRT) or locoregional therapy must show radiographic evidence of disease progression based on RECIST 1.1 to be deemed a target lesion.\n\n3.Karnofsky Performance Status (KPS) of \\>=70 4.Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than or equal (\\<=) 150/90 millimeter of mercury (mmHg) at Screening and no change in antihypertensive medications within 1 week prior to Cycle 1/Day 1 (C1/D1) 5.Adequate renal function defined as creatinine \\<=1.5\\*upper limit of normal (ULN); or for participants with creatinine greater than (\\>) 1.5\\*ULN, the calculated creatinine clearance \\>=30 milliliters per minute (mL/min) (per the Cockcroft-Gault formula) is acceptable.\n\n6.Adequate bone marrow function defined by:\n\n* Absolute neutrophil count (ANC) \\>=1500/cubic millimeter (mm\\^3)\n* Platelets \\>=100,000/mm\\^3\n* Hemoglobin \\>=9 grams per deciliter (g/dL) NOTE: Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within the previous 2 weeks.\n\n 7.Adequate blood coagulation function defined by International Normalized ratio (INR) \\<=1.5 unless participant is receiving anticoagulant therapy, as long as INR is within therapeutic range of intended use of anticoagulants.\n\n 8.Adequate liver function defined by:\n* Total bilirubin \\<=1.5\\*ULN except for unconjugated hyperbilirubinemia of Gilbert's syndrome.\n* Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) \\<=3\\*ULN (in the case of liver metastases \\<=5\\*ULN), unless there are bone metastases. Participants with ALP values \\>3\\*ULN and known to have bone metastases can be included.\n\n 9.Provide written informed consent. 10.Willing and able to comply with all aspects of the protocol.\n\nExclusion Criteria:\n\n1. Participants who have received any systemic anticancer therapy for RCC, including anti-vascular endothelial growth factor (VEGF) therapy, or any systemic investigational anticancer agent. Prior adjuvant treatment with an investigational anticancer agent is not allowed unless the investigator can provide evidence of participant's randomization to placebo arm.\n2. Participants with central nervous system (CNS) metastases are not eligible, unless they have completed local therapy (example, whole brain radiation therapy (WBRT), surgery or radiosurgery) and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (example, radiologic) or symptoms of CNS metastases must be stable for at least 4 weeks before starting study treatment\n3. Active malignancy (except for RCC, definitively treated basal or squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix or bladder) within the past 24 months. Participants with history of localized \\& low risk prostate cancer are allowed in the study if they were treated with curative intent and there is no prostate specific antigen (PSA) recurrence within the past 5 years\n4. Prior radiation therapy within 21 days prior to start of study treatment with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks prior to study treatment start\n5. Participants who are using other investigational agents or who had received investigational drugs \\<=4 weeks prior to study treatment start.\n6. Received a live vaccine within 30 days of planned start of study treatment (Cycle 1/Day 1). Examples of live vaccines include, but are not limited to, measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (example, FluMist®) are live attenuated vaccines and are not allowed.\n7. Participants with proteinuria \\>1+ on urine dipstick testing will undergo 24-h urine collection for quantitative assessment of proteinuria. Participants with urine protein \\>=1 g/24 h will be ineligible\n8. Fasting total cholesterol \\>300 milligram per deciliter (mg/dL) (or ˃7.75 millimole per liter (mmol/L)) and/or fasting triglycerides level ˃2.5 x upper limit of normal (ULN). Note: these participants can be included after initiation or adjustment of lipid-lowering medication\n9. Uncontrolled diabetes as defined by fasting glucose \\>1.5 times the ULN. Note: these participants can be included after initiation or adjustment of glucose-lowering medication\n10. Prolongation of corrected QT (QTc) interval to \\>480 milliseconds (ms)\n11. Participants who have not recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy.\n12. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib, everolimus, and/or sunitinib.\n13. Bleeding or thrombotic disorders or participants at risk for severe hemorrhage. The degree of tumor invasion/infiltration of major blood vessels should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis following lenvatinib therapy\n14. Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug\n15. Significant cardiovascular impairment within 12 months of the first dose of study drug: history of congestive heart failure greater than New York Heart Association Class II, unstable angina, myocardial infarction, cerebrovascular accident, or cardiac arrhythmia associated with hemodynamic instability. The following is also excluded: left ventricular ejection fraction (LVEF) below the institutional normal range as determined by multiple-gated acquisition MUGA scan or echocardiogram\n16. Active infection (any infection requiring systemic treatment)\n17. Participants known to be positive for Human Immunodeficiency Virus (HIV).\n18. Known active Hepatitis B (example, Hepatitis B surface antigen (HBsAg) reactive) or Hepatitis C (example, hepatitis C virus ribonucleic acid (HCV RNA) \\[qualitative\\] is detected)\n19. Known history of, or any evidence of, interstitial lung disease\n20. Has a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis\n21. Participants with a diagnosis of immunodeficiency or who are receiving chronic systemic steroid therapy (doses exceeding 10 mg/day of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. Physiologic doses of corticosteroids (up to 10 mg/day of prednisone or equivalent) may be used during the study\n22. Active autoimmune disease (with the exception of psoriasis) that has required systemic treatment in the past 2 years (that is, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (example, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.\n23. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin \\[ß-hCG\\] (or human chorionic gonadotropin \\[hCG\\]) test with a minimum sensitivity of 25 IU/L or equivalent units of ß-hCG \\[or hCG\\]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.\n24. Females of childbearing potential who:\n\n * Do not agree to use a highly effective method of contraception for the entire study period and for 120 days after study discontinuation, that is:\n * total abstinence (if it is their preferred and usual lifestyle)\n * an intrauterine device (IUD) or hormone-releasing system (IUS)\n * a contraceptive implant\n * an oral contraceptive (with additional barrier method) OR\n * Do not have a vasectomized partner with confirmed azoospermia. For sites outside of the EU, it is permissible that if a highly effective method of contraception is not appropriate or acceptable to the participant, then the participant must agree to use a medically acceptable method of contraception, that is, double barrier methods of contraception such as condom plus diaphragm or cervical/vault cap with spermicide.\n25. Males who have not had a successful vasectomy (confirmed azoospermia) and do not agree to use condom + spermicide OR have a female partner who does not meet the criteria above (that is, is of childbearing potential and not practicing highly effective contraception throughout the study period), starting with the first dose of study therapy through 120 days after the last dose of study therapy, unless sexually abstinent. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant.\n26. Known intolerance to any of the study drugs (or any of the excipients)\n27. Participant has had an allogenic tissue/solid organ transplant."}, 'identificationModule': {'nctId': 'NCT02811861', 'acronym': 'CLEAR', 'briefTitle': 'Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma', 'organization': {'class': 'INDUSTRY', 'fullName': 'Eisai Inc.'}, 'officialTitle': 'A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR)', 'orgStudyIdInfo': {'id': 'E7080-G000-307'}, 'secondaryIdInfos': [{'id': 'KEYNOTE-581', 'type': 'OTHER', 'domain': 'Merck'}, {'id': '2016-000916-14', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Lenvatinib 18 mg plus Everolimus 5 mg', 'description': 'Lenvatinib 18 milligrams (mg) administered orally, once daily, plus everolimus 5 mg administered orally, once daily in each 21-day cycle.', 'interventionNames': ['Drug: Lenvatinib', 'Drug: Everolimus']}, {'type': 'EXPERIMENTAL', 'label': 'Lenvatinib 20 mg plus Pembrolizumab 200 mg', 'description': 'Lenvatinib 20 mg administered orally, once daily, in each 21-day cycle plus pembrolizumab 200 mg administered intravenously (IV), every 3 weeks on Day 1 of each 21-day cycle.', 'interventionNames': ['Drug: Lenvatinib', 'Drug: Pembrolizumab']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Sunitinib 50 mg', 'description': 'Sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment in each 21-day cycle.', 'interventionNames': ['Drug: Sunitinib']}], 'interventions': [{'name': 'Lenvatinib', 'type': 'DRUG', 'armGroupLabels': ['Lenvatinib 18 mg plus Everolimus 5 mg', 'Lenvatinib 20 mg plus Pembrolizumab 200 mg']}, {'name': 'Everolimus', 'type': 'DRUG', 'armGroupLabels': ['Lenvatinib 18 mg plus Everolimus 5 mg']}, {'name': 'Pembrolizumab', 'type': 'DRUG', 'armGroupLabels': ['Lenvatinib 20 mg plus Pembrolizumab 200 mg']}, {'name': 'Sunitinib', 'type': 'DRUG', 'armGroupLabels': ['Sunitinib 50 mg']}]}, 'contactsLocationsModule': {'locations': [{'zip': '94305-5826', 'city': 'Stanford', 'state': 'California', 'country': 'United States', 'facility': 'Stanford School of Medicine', 'geoPoint': {'lat': 37.42411, 'lon': -122.16608}}, {'zip': '33486', 'city': 'Boca Raton', 'state': 'Florida', 'country': 'United States', 'facility': 'Boca Raton Community Hospital', 'geoPoint': {'lat': 26.35869, 'lon': -80.0831}}, {'zip': '33901', 'city': 'Fort Myers', 'state': 'Florida', 'country': 'United States', 'facility': 'Florida Cancer Specialists', 'geoPoint': {'lat': 26.62168, 'lon': -81.84059}}, {'zip': '33136', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'University of Miami', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33136', 'city': 'Miami Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'Mount Sinai Medical Center', 'geoPoint': {'lat': 25.79065, 'lon': -80.13005}}, {'zip': '32804', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Florida Hospital Cancer Institute', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '33705', 'city': 'St. Petersburg', 'state': 'Florida', 'country': 'United States', 'facility': 'Florida Cancer Specialists ( North Region)', 'geoPoint': {'lat': 27.77086, 'lon': -82.67927}}, {'zip': '33401', 'city': 'West Palm Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'Florida Cancer Specialists', 'geoPoint': {'lat': 26.71534, 'lon': -80.05337}}, {'zip': '60435', 'city': 'Joliet', 'state': 'Illinois', 'country': 'United States', 'facility': 'Joliet Oncology - Hematology Associates', 'geoPoint': {'lat': 41.52519, 'lon': -88.0834}}, {'zip': '60487', 'city': 'Tinley Park', 'state': 'Illinois', 'country': 'United States', 'facility': 'Healthcare Research Network III, LLC', 'geoPoint': {'lat': 41.57337, 'lon': -87.78449}}, {'zip': '66209', 'city': 'Overland Park', 'state': 'Kansas', 'country': 'United States', 'facility': 'Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC', 'geoPoint': {'lat': 38.98223, 'lon': -94.67079}}, {'zip': '66604', 'city': 'Topeka', 'state': 'Kansas', 'country': 'United States', 'facility': 'Cotton-Oneil Clinical Research Center', 'geoPoint': {'lat': 39.04833, 'lon': -95.67804}}, {'zip': '70121', 'city': 'New Orleans', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Ochsner Clinic Foundation', 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'zip': '20817', 'city': 'Bethesda', 'state': 'Maryland', 'country': 'United States', 'facility': 'Associates in Oncology & Hematology, PC', 'geoPoint': {'lat': 38.98067, 'lon': -77.10026}}, {'zip': '02214', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Massachusetts General Hospital- MGH', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '02215', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Dana Farber Cancer Institute', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '48201', 'city': 'Detroit', 'state': 'Michigan', 'country': 'United States', 'facility': 'Karmanos Cancer Center', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '68130', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'facility': 'GU Research Network', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '68130', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Nebraska Cancer Specialists', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '07601', 'city': 'Hackensack', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Hackensack Medical Center', 'geoPoint': {'lat': 40.88593, 'lon': -74.04347}}, {'zip': '14263', 'city': 'Buffalo', 'state': 'New York', 'country': 'United States', 'facility': 'Rosewell Park Cancer Institute', 'geoPoint': {'lat': 42.88645, 'lon': -78.87837}}, {'zip': '13790', 'city': 'Johnson City', 'state': 'New York', 'country': 'United States', 'facility': 'Broome Oncology', 'geoPoint': {'lat': 42.11563, 'lon': -75.95881}}, {'zip': '10021', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Weill Cornell Medical College New York Presbyterian Hospital', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Memorial Sloan Kettering Cancer Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10461', 'city': 'The Bronx', 'state': 'New York', 'country': 'United States', 'facility': 'Montefiore Medical Center', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'zip': '28801', 'city': 'Asheville', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Mission Hospital_ Cancer Care of Western North Carolina', 'geoPoint': {'lat': 35.60095, 'lon': -82.55402}}, {'zip': '45242', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'Oncology Hematology Care', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '29412', 'city': 'Charleston', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Medical University of South Carolina', 'geoPoint': {'lat': 32.77632, 'lon': -79.93275}}, {'zip': '37203', 'city': 'Nashville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'SCRI - Tennessee Oncology', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '75231', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Texas Oncology, P.A.', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '76104', 'city': 'Fort Worth', 'state': 'Texas', 'country': 'United States', 'facility': 'Texas Oncology PA', 'geoPoint': {'lat': 32.72541, 'lon': -97.32085}}, {'zip': '78503', 'city': 'McAllen', 'state': 'Texas', 'country': 'United States', 'facility': 'Texas Oncology PA - McAllen', 'geoPoint': {'lat': 26.20341, 'lon': -98.23001}}, {'zip': '75460', 'city': 'Paris', 'state': 'Texas', 'country': 'United States', 'facility': 'Texas Oncology PA - Paris', 'geoPoint': {'lat': 33.66094, 'lon': -95.55551}}, {'zip': '77380', 'city': 'The Woodlands', 'state': 'Texas', 'country': 'United States', 'facility': 'USOR Texas Oncology', 'geoPoint': {'lat': 30.15799, 'lon': -95.48938}}, {'zip': '75702', 'city': 'Tyler', 'state': 'Texas', 'country': 'United States', 'facility': 'Texas Oncology PA - Tyler', 'geoPoint': {'lat': 32.35126, 'lon': -95.30106}}, {'zip': '3128', 'city': 'Box Hill', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Box Hill Hospital', 'geoPoint': {'lat': -37.81887, 'lon': 145.12545}}, {'zip': '3084', 'city': 'Heidelberg', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Austin Health', 'geoPoint': {'lat': -37.75, 'lon': 145.06667}}, {'city': 'Hobart', 'country': 'Australia', 'facility': 'Royal Hobart Hospital', 'geoPoint': {'lat': -42.87936, 'lon': 147.32941}}, {'city': 'Macquarie Park', 'country': 'Australia', 'facility': 'Macquarie University Hospital', 'geoPoint': {'lat': -33.78105, 'lon': 151.12757}}, {'city': 'South Brisbane', 'country': 'Australia', 'facility': 'ICON Cancer Foundation', 'geoPoint': {'lat': -27.48034, 'lon': 153.02049}}, {'city': 'St Albans', 'country': 'Australia', 'facility': 'Sunshine Hospital', 'geoPoint': {'lat': -37.74496, 'lon': 144.80049}}, {'city': 'Innsbruck', 'country': 'Austria', 'facility': 'Medizinische Universitat Innsbruck', 'geoPoint': {'lat': 47.26266, 'lon': 11.39454}}, {'city': 'Linz', 'country': 'Austria', 'facility': 'Krankenhaus der barmherzigen Schwestern Linz', 'geoPoint': {'lat': 48.30639, 'lon': 14.28611}}, {'zip': '1090', 'city': 'Vienna', 'country': 'Austria', 'facility': 'AKH - Medizinische Universität Wien', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'city': 'Aalst', 'country': 'Belgium', 'facility': 'O.L.V Ziekenhuis', 'geoPoint': {'lat': 50.93604, 'lon': 4.0355}}, {'zip': '2260', 'city': 'Antwerp', 'country': 'Belgium', 'facility': 'ZNA Middelheim', 'geoPoint': {'lat': 51.22047, 'lon': 4.40026}}, {'city': 'Bonheiden', 'country': 'Belgium', 'facility': 'Imeldaziekenhuis', 'geoPoint': {'lat': 51.02261, 'lon': 4.54714}}, {'zip': '1000', 'city': 'Brussels', 'country': 'Belgium', 'facility': 'Institut Jules Bordet', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '3500', 'city': 'Hasselt', 'country': 'Belgium', 'facility': 'Jessa Ziekenhuis - Campus Virga Jesse', 'geoPoint': {'lat': 50.93106, 'lon': 5.33781}}, {'zip': '4000', 'city': 'Liège', 'country': 'Belgium', 'facility': 'Domaine Universitaire', 'geoPoint': {'lat': 50.63373, 'lon': 5.56749}}, {'zip': '2610', 'city': 'Wilrijk', 'country': 'Belgium', 'facility': 'GZA Ziekenhuizen - Campus Sint-Augustinus', 'geoPoint': {'lat': 51.16734, 'lon': 4.39513}}, {'zip': 'T6G 1Z2', 'city': 'Edmonton', 'state': 'Alberta', 'country': 'Canada', 'facility': 'Cross Cancer Institute', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'zip': 'V5Z 1H7', 'city': 'Vancouver', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'BC Cancer Agency Vancouver Centre', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'zip': 'L8N 4A6', 'city': 'Hamilton', 'state': 'Ontario', 'country': 'Canada', 'facility': "St. Joseph's Healthcare Hamilton", 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}}, {'zip': 'N6A4L6', 'city': 'London', 'state': 'Ontario', 'country': 'Canada', 'facility': 'London Institute of Health Sciences', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'zip': 'K1H 8', 'city': 'Ottawa', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Ottawa Hospital Cancer Centre', 'geoPoint': {'lat': 45.41117, 'lon': -75.69812}}, {'zip': 'M4N 3M5', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Sunnybrook Research Institute - University of Toronto', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'J4V 2H1', 'city': 'Greenfield Park', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Centre de santé et de services sociaux Champlain-Charles-Le Moyne', 'geoPoint': {'lat': 45.48649, 'lon': -73.46223}}, {'city': 'Brno', 'country': 'Czechia', 'facility': 'Fakultni nemocnice u sv. Anny v Brne', 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}}, {'city': 'Brno', 'country': 'Czechia', 'facility': 'Masarykuv onkologicky ustav', 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}}, {'city': 'Olomouc', 'country': 'Czechia', 'facility': 'Fakultni nemocnice Olomouc, Neurologicka klinika', 'geoPoint': {'lat': 49.59552, 'lon': 17.25175}}, {'city': 'Prague', 'country': 'Czechia', 'facility': 'Fakultni nemocnice v Motole', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'city': 'Prague', 'country': 'Czechia', 'facility': 'Nemocnice Na Bulovce', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'city': 'Prague', 'country': 'Czechia', 'facility': 'Thomayerova nemocnice', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '49055', 'city': 'Angers', 'state': 'Maine Et Loire', 'country': 'France', 'facility': 'ICO - Site Paul Papin', 'geoPoint': {'lat': 47.47156, 'lon': -0.55202}}, {'zip': '21079', 'city': 'Dijon', 'country': 'France', 'facility': 'Centre Georges François Leclerc', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'city': 'Le Mans', 'country': 'France', 'facility': 'Clinique Victor Hugo - Centre Jean Bernard', 'geoPoint': {'lat': 48.0021, 'lon': 0.20251}}, {'city': 'Lyon', 'country': 'France', 'facility': 'Centre Leon Berard - Centre regional de lutte contre le cancer Rhone-Alpes', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'city': 'Montpellier', 'country': 'France', 'facility': 'Institut Regional du Cancer de Montpellier', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'zip': 'cedex 13 75651', 'city': 'Paris', 'country': 'France', 'facility': 'Hopital la Petie Salpetriere', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Paris', 'country': 'France', 'facility': 'Hopital Europeen Georges Pompidou', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '4805', 'city': 'Saint-Herblain', 'country': 'France', 'facility': 'Boulevard du Professeur Jacques Monod', 'geoPoint': {'lat': 47.21154, 'lon': -1.651}}, {'city': 'Strasbourg', 'country': 'France', 'facility': 'CHU Strasbourg - Nouvel Hopital Civil', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'zip': '70174', 'city': 'Stuttgart', 'state': 'Baden-Wurttemberg', 'country': 'Germany', 'facility': 'EISAI Trial site 4', 'geoPoint': {'lat': 48.78232, 'lon': 9.17702}}, {'zip': '72076', 'city': 'Tübingen', 'state': 'Baden-Wurttemberg', 'country': 'Germany', 'facility': 'EISAI Trial site 1', 'geoPoint': {'lat': 48.52266, 'lon': 9.05222}}, {'zip': '81377', 'city': 'München', 'state': 'Bavaria', 'country': 'Germany', 'facility': 'EISAI Trial site 7', 'geoPoint': {'lat': 48.69668, 'lon': 13.46314}}, {'zip': '60590', 'city': 'Frankfurt am Main', 'state': 'Hesse', 'country': 'Germany', 'facility': 'EISAI Trial site 6', 'geoPoint': {'lat': 50.11552, 'lon': 8.68417}}, {'zip': '30625', 'city': 'Hanover', 'state': 'Lower Saxony', 'country': 'Germany', 'facility': 'EISAI Trial site 8', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'city': 'Greifswald', 'state': 'Mecklenburg-Vorpommern', 'country': 'Germany', 'facility': 'EISAI Trial site 14', 'geoPoint': {'lat': 54.08905, 'lon': 13.40244}}, {'zip': '48149', 'city': 'Münster', 'state': 'North Rhine-Westphalia', 'country': 'Germany', 'facility': 'EISAI Trial site 13', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}}, {'zip': '66421', 'city': 'Homburg/Saar', 'state': 'Saarland', 'country': 'Germany', 'facility': 'EISAI Trial site 2'}, {'zip': '12200', 'city': 'Berlin', 'country': 'Germany', 'facility': 'EISAI Trial site 5', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '11528', 'city': 'Athens', 'country': 'Greece', 'facility': 'General Hospital of Athens "Alexandra"', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '26504', 'city': 'Pátrai', 'country': 'Greece', 'facility': 'University of Patras Medical School', 'geoPoint': {'lat': 38.2462, 'lon': 21.73508}}, {'zip': '56429', 'city': 'Thessaloniki', 'country': 'Greece', 'facility': 'General Hospital Papageorgiou', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'zip': '57001', 'city': 'Thessaloniki', 'country': 'Greece', 'facility': 'Interbalkan Hospital of Thessaloniki', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'city': 'Cork', 'country': 'Ireland', 'facility': 'Cork University Hospital,Wilton', 'geoPoint': {'lat': 51.89797, 'lon': -8.47061}}, {'city': 'Dublin', 'country': 'Ireland', 'facility': "Adelaide and Meath Hospital Incorp The National Children's Hospital", 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'city': 'Dublin', 'country': 'Ireland', 'facility': 'Beaumont Hospital', 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'city': 'Galway', 'country': 'Ireland', 'facility': 'University Hospital Galway', 'geoPoint': {'lat': 53.27245, 'lon': -9.05095}}, {'city': 'Be’er Ya‘aqov', 'country': 'Israel', 'facility': 'Assaf Harofeh Medical Center', 'geoPoint': {'lat': 31.93864, 'lon': 34.83749}}, {'city': 'Haifa', 'country': 'Israel', 'facility': 'Rambam MC', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'city': 'Kfar Saba', 'country': 'Israel', 'facility': 'Sapir Medical Center, Meir Hospital', 'geoPoint': {'lat': 32.175, 'lon': 34.90694}}, {'zip': '49100', 'city': 'Petah Tikva', 'country': 'Israel', 'facility': 'Rabin Medical Center-Beilinson Campus', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'city': 'Ramat Gan', 'country': 'Israel', 'facility': 'Chaim Sheba Medical Center', 'geoPoint': {'lat': 32.08227, 'lon': 34.81065}}, {'city': 'Tel Aviv', 'country': 'Israel', 'facility': 'Tel Aviv Sourasky Medical Center', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'zip': '48018', 'city': 'Faenza', 'state': 'Ravenna', 'country': 'Italy', 'facility': 'Azienda Unità Sanitaria Locale- Ravenna', 'geoPoint': {'lat': 44.29007, 'lon': 11.87948}}, {'city': 'Arezzo', 'country': 'Italy', 'facility': 'Ospedale San Donato', 'geoPoint': {'lat': 43.46276, 'lon': 11.88068}}, {'city': 'Bologna', 'country': 'Italy', 'facility': 'Azienda Ospedaliera Universitaria Policlinico SantOrsola Malpighi', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'zip': '16132', 'city': 'Genova', 'country': 'Italy', 'facility': 'Istituto Nazionale per la Ricerca sul Cancro di Genova', 'geoPoint': {'lat': 45.21604, 'lon': 11.87211}}, {'zip': '73100', 'city': 'Lecce', 'country': 'Italy', 'facility': 'Presidio Ospedaliero Vito Fazzi', 'geoPoint': {'lat': 40.35481, 'lon': 18.17244}}, {'city': 'Meldola', 'country': 'Italy', 'facility': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST', 'geoPoint': {'lat': 44.12775, 'lon': 12.0626}}, {'zip': '20133', 'city': 'Milan', 'country': 'Italy', 'facility': 'Fondazione IRCCS Istituto Nazionale dei Tumori', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '41124', 'city': 'Modena', 'country': 'Italy', 'facility': 'A.O.U. Policlinico di Modena', 'geoPoint': {'lat': 44.64783, 'lon': 10.92539}}, {'zip': '80131', 'city': 'Napoli', 'country': 'Italy', 'facility': 'Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'city': 'Napoli', 'country': 'Italy', 'facility': 'Istituto Nazionale Tumori Fondazione G. Pascale', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'city': 'Pavia', 'country': 'Italy', 'facility': 'Fondazione IRCCS Policlinico San Matteo', 'geoPoint': {'lat': 45.19205, 'lon': 9.15917}}, {'city': 'Pavia', 'country': 'Italy', 'facility': 'I.R.C.S.S Fondazione Maugeri', 'geoPoint': {'lat': 45.19205, 'lon': 9.15917}}, {'zip': '33170', 'city': 'Pordenone', 'country': 'Italy', 'facility': 'Azienda Ospedaliera Santa Maria Degli Angeli', 'geoPoint': {'lat': 45.95689, 'lon': 12.66051}}, {'city': 'Roma', 'country': 'Italy', 'facility': 'Azienda Ospedaliera San Camillo Forlanini', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'city': 'Rome', 'country': 'Italy', 'facility': 'Universita Campus Bio-Medico di Roma', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'city': 'Aichi', 'country': 'Japan', 'facility': 'Facility #1', 'geoPoint': {'lat': 32.51879, 'lon': 130.62158}}, {'city': 'Akita', 'country': 'Japan', 'facility': 'Facility #1', 'geoPoint': {'lat': 39.71667, 'lon': 140.11667}}, {'city': 'Aomori', 'country': 'Japan', 'facility': 'Facility #1', 'geoPoint': {'lat': 40.81667, 'lon': 140.73333}}, {'city': 'Chiba', 'country': 'Japan', 'facility': 'Facility #2', 'geoPoint': {'lat': 35.6, 'lon': 140.11667}}, {'city': 'Fukuoka', 'country': 'Japan', 'facility': 'Facility #1', 'geoPoint': {'lat': 33.6, 'lon': 130.41667}}, {'city': 'Hiroshima', 'country': 'Japan', 'facility': 'Facility #1', 'geoPoint': {'lat': 34.4, 'lon': 132.45}}, {'city': 'Hokkaido', 'country': 'Japan', 'facility': 'Facility #1'}, {'city': 'Hokkaido', 'country': 'Japan', 'facility': 'Facility #2'}, {'city': 'Hyōgo', 'country': 'Japan', 'facility': 'Facility #1', 'geoPoint': {'lat': 43.36667, 'lon': 144.43333}}, {'city': 'Kagawa', 'country': 'Japan', 'facility': 'Facility #1', 'geoPoint': {'lat': 34.06667, 'lon': 131.03333}}, {'city': 'Kanagawa', 'country': 'Japan', 'facility': 'Facility #2', 'geoPoint': {'lat': 37.58333, 'lon': 139.91667}}, {'city': 'Kanagawa', 'country': 'Japan', 'facility': 'Facility #3', 'geoPoint': {'lat': 37.58333, 'lon': 139.91667}}, {'city': 'Nagasaki', 'country': 'Japan', 'facility': 'Facility #1', 'geoPoint': {'lat': 32.75, 'lon': 129.88333}}, {'city': 'Nara', 'country': 'Japan', 'facility': 'Facility #1', 'geoPoint': {'lat': 34.68505, 'lon': 135.80485}}, {'city': 'Niigata', 'country': 'Japan', 'facility': 'Facility #1', 'geoPoint': {'lat': 37.92259, 'lon': 139.04125}}, {'city': 'Okayama', 'country': 'Japan', 'facility': 'Facility #1', 'geoPoint': {'lat': 34.65, 'lon': 133.93333}}, {'city': 'Osaka', 'country': 'Japan', 'facility': 'Facility #1', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}, {'city': 'Osaka', 'country': 'Japan', 'facility': 'Facility #2', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}, {'city': 'Saitama', 'country': 'Japan', 'facility': 'Facility #1', 'geoPoint': {'lat': 35.90807, 'lon': 139.65657}}, {'city': 'Tokushima', 'country': 'Japan', 'facility': 'Facility #1', 'geoPoint': {'lat': 34.06667, 'lon': 134.56667}}, {'city': 'Tokyo', 'country': 'Japan', 'facility': 'Facility #1', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'city': 'Tokyo', 'country': 'Japan', 'facility': 'Facility #2', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'city': 'Tokyo', 'country': 'Japan', 'facility': 'Facility #3', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'city': 'Tokyo', 'country': 'Japan', 'facility': 'Facility #4', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'city': 'Tokyo', 'country': 'Japan', 'facility': 'Facility #5', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'city': 'Tokyo', 'country': 'Japan', 'facility': 'Facility #6', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'zip': '1066 CX', 'city': 'Amsterdam', 'country': 'Netherlands', 'facility': 'Antoni van Leeuwenhoek', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'zip': '1081 HV', 'city': 'Amsterdam', 'country': 'Netherlands', 'facility': 'VU Medisch Centrum', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'zip': '3584 CX', 'city': 'Utrecht', 'country': 'Netherlands', 'facility': 'UMC Utrecht', 'geoPoint': {'lat': 52.09083, 'lon': 5.12222}}, {'city': 'Gdansk', 'country': 'Poland', 'facility': 'Uniwersyteckie Centrum Kliniczne', 'geoPoint': {'lat': 54.35227, 'lon': 18.64912}}, {'city': 'Lublin', 'country': 'Poland', 'facility': 'Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'city': 'Szczecin', 'country': 'Poland', 'facility': 'SPWSZ w Szczecinie im. Marii Sklodowskiej-Curie', 'geoPoint': {'lat': 53.42894, 'lon': 14.55302}}, {'zip': '115478', 'city': 'Moscow', 'country': 'Russia', 'facility': 'FSBSI Russian Oncological Scientific Center n.a. N.N. Blokhin - Department of Oncology', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '125284', 'city': 'Moscow', 'country': 'Russia', 'facility': 'FSBI "Moscow scientific research oncology institute n.a. P.A. Gertsen" of MoH of RF', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Moscow', 'country': 'Russia', 'facility': 'FSBSI Russian Oncological Scientific Center n.a. N.N. Blokhin - Department of Urology', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Nizhny Novgorod', 'country': 'Russia', 'facility': 'FBHI Privolzhskiy District Medical Centre FMBA of Russia', 'geoPoint': {'lat': 56.32867, 'lon': 44.00205}}, {'zip': '630108', 'city': 'Novosibirsk', 'country': 'Russia', 'facility': 'SBHI of Novosibirsk region "Novosibirsk Regional Oncological Dispensary"', 'geoPoint': {'lat': 55.02259, 'lon': 82.93175}}, {'zip': '249036', 'city': 'Obninsk', 'country': 'Russia', 'facility': 'FSBI "National Medical Research Radiological Center" of the MoH of the RF', 'geoPoint': {'lat': 55.10993, 'lon': 36.61238}}, {'zip': '644013', 'city': 'Omsk', 'country': 'Russia', 'facility': 'BHI of Omsk region "Clinical Oncology Dispensary"', 'geoPoint': {'lat': 54.99244, 'lon': 73.36859}}, {'zip': '41404', 'city': 'Daegu', 'country': 'South Korea', 'facility': 'Kyungpook National University Chilgok Hospital', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}, {'city': 'Goyang-si', 'country': 'South Korea', 'facility': 'National Cancer Center', 'geoPoint': {'lat': 37.65639, 'lon': 126.835}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Asan Medical Center: Medical Oncology Department', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Asan Medical Center: Urology Department', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Department of Internal Medicine Division of Hematology/Oncology Cancer center 11F', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Samsung Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Severance Hospital, Yonsei University Health System', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': "The Catholic University of Korea, Seoul St. Mary's Hospital", 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '39008', 'city': 'Santander', 'state': 'Cantabria', 'country': 'Spain', 'facility': 'Hospital Universitario Marques de Valdecilla', 'geoPoint': {'lat': 43.46589, 'lon': -3.80493}}, {'zip': '08036', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital Clinic i Provincial de Barcelona', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08908', 'city': 'Barcelona', 'country': 'Spain', 'facility': "ICO l'Hospitalet - Hospital Duran I Reynals", 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital de la Santa Creu i Sant Pau', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'city': 'Barcelona', 'country': 'Spain', 'facility': "Hospital Universitari Vall d'Hebron", 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '10003', 'city': 'Cáceres', 'country': 'Spain', 'facility': 'Hospital San Pedro de Alcantara', 'geoPoint': {'lat': 39.47649, 'lon': -6.37224}}, {'city': 'Córdoba', 'country': 'Spain', 'facility': 'Hospital Universitario Reina Sofia', 'geoPoint': {'lat': 37.89155, 'lon': -4.77275}}, {'zip': '28034', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario Ramon y Cajal', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital General Universitario Gregorio Maranon', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario Clinico San Carlos', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario HM Madrid Sanchinarro', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'MD Anderson Cancer Centre', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '33011', 'city': 'Oviedo', 'country': 'Spain', 'facility': 'Hospital Universitario Central de Asturias', 'geoPoint': {'lat': 43.36029, 'lon': -5.84476}}, {'city': 'Seville', 'country': 'Spain', 'facility': 'Hospital Universitario Virgen del Rocio', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '46009', 'city': 'Valencia', 'country': 'Spain', 'facility': 'Oncologia', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'city': 'Bern', 'country': 'Switzerland', 'facility': 'Inselspital - Universitaetsspital Bern', 'geoPoint': {'lat': 46.94809, 'lon': 7.44744}}, {'city': 'Bournemouth', 'country': 'United Kingdom', 'facility': 'Royal Bournemouth General Hospital', 'geoPoint': {'lat': 50.72048, 'lon': -1.8795}}, {'city': 'Cardiff', 'country': 'United Kingdom', 'facility': 'Velindre Cancer Centre', 'geoPoint': {'lat': 51.48, 'lon': -3.18}}, {'city': 'Edinburgh', 'country': 'United Kingdom', 'facility': 'Western General Hospital', 'geoPoint': {'lat': 55.95206, 'lon': -3.19648}}, {'zip': 'G12 0YN', 'city': 'Glasgow', 'country': 'United Kingdom', 'facility': 'Beatson West Of Scotland Cancer Centre', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'zip': 'LS9 7TF', 'city': 'Leeds', 'country': 'United Kingdom', 'facility': "St. James's University Hospital", 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}, {'city': 'London', 'country': 'United Kingdom', 'facility': "Guy's Hospital", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'London', 'country': 'United Kingdom', 'facility': 'Royal Free Hospital', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'M20 4BX', 'city': 'Manchester', 'country': 'United Kingdom', 'facility': 'Christie Hospital NHS Foundation Trust', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Eisai Inc.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Merck Sharp & Dohme LLC', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}